Clareo Health | A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Duramed Research
The study will include a screening period up to 4 weeks and a 12- week treatment period. The overall study duration for participants will be approximately 16 weeks. Study participants will undergo physical and gynecological exams, and blood tests for clinical laboratory assessments. All patients with a uterus will undergo transvaginal ultrasound.
Age
30–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Naturally or surgically menopausal
Moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse)
You may not be if
Known sensitivity or contraindication to estrogens or progestins
History or current diagnosis endometrial hyperplasia
Recent history of vaginal bleeding of unknown cause
